Here is Why Growth Investors Should Buy ResMed (RMD) Now

Core Viewpoint - Investors are increasingly seeking growth stocks that demonstrate above-average growth potential, with ResMed (RMD) identified as a strong candidate due to its favorable growth metrics and Zacks Rank [2][10]. Group 1: Earnings Growth - ResMed has a historical EPS growth rate of 13.3%, with projected EPS growth of 18.6% for the current year, surpassing the industry average of 13.6% [5]. Group 2: Cash Flow Growth - The year-over-year cash flow growth for ResMed stands at 9.8%, significantly higher than the industry average of -12.5% [6]. - Over the past 3-5 years, ResMed's annualized cash flow growth rate has been 12.8%, compared to the industry average of 6% [7]. Group 3: Earnings Estimate Revisions - There has been a positive trend in earnings estimate revisions for ResMed, with the Zacks Consensus Estimate for the current year increasing by 2.7% over the past month [9]. Group 4: Overall Positioning - ResMed has achieved a Growth Score of A and holds a Zacks Rank of 2, indicating strong potential for outperformance in the growth stock category [10].